Sublimity To Present at Three Life science Investment Conferences
February 27, 2020 06:50 ET
|
Sublimity Therapeutics Limited
SOLANA BEACH, Calif., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Sublimity Therapeutics, a biopharmaceutical company focused on creating meaningful new treatments for GI and immunological diseases, today...
Sublimity To Present at Three Life science Investment Conferences
February 27, 2020 06:00 ET
|
Sublimity Therapeutics Limited
SOLANA BEACH, Calif., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Sublimity Therapeutics, a biopharmaceutical company focused on creating meaningful new treatments for GI and immunological diseases, today...
Sublimity Therapeutics Receives Investigational New Drug (IND) Clearance from U.S. Food and Drug Administration (FDA)
January 07, 2019 09:00 ET
|
Sublimity Therapeutics Limited
Company also Receives Ireland Authorization and Health Canada Clearance Phase 2b Clinical Trial of ST-0529 for the Treatment of Ulcerative Colitis to Launch This Month SAN DIEGO, Jan. 07, 2019 ...
Sublimity Therapeutics Appoints Jesse W. Hall as Chief Medical Officer
July 30, 2018 06:00 ET
|
Sublimity Therapeutics Limited
DUBLIN, Ireland, July 30, 2018 (GLOBE NEWSWIRE) -- Sublimity Therapeutics, a specialty pharmaceutical company focused on the treatment of ulcerative colitis, today announced the appointment of...
Sublimity Therapeutics Closes US$64 Million Financing to Fund Development of New Oral Ulcerative Colitis Drug Candidate
May 22, 2018 06:00 ET
|
Sublimity Therapeutics Limited
DUBLIN, Ireland, May 22, 2018 (GLOBE NEWSWIRE) -- Sublimity Therapeutics Limited (formerly Sigmoid Pharma Limited), a specialty pharmaceutical company focused on the treatment of ulcerative colitis,...